Study S001533

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05579249
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 500
Start: 2023-01-19
Primary completion: 2024-11-27
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Semaglutide; DRUG:Orlistat; DRUG:Phentermine/Topiramate; DRUG:Naltrexone/Bupropion; DRUG:Liraglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1263-7301

Registered primary outcomes

Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) [At end of treatment (week 52)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.